Highest-materiality recent filing
CEO Richard Paulson receives $1.725M; CFO Lori Macomber $625K; CMO Reshma Rangwala $725K; CDO Stuart Poulton $640K.
Karyopharm Q1 revenue $35.1M, net loss $22.4M; Phase 3 endometrial trial enrollment complete
U.S. XPOVIO net product revenue $29.2M (up from $21.1M YoY) on lower gross-to-net adjustments.
Karyopharm raises ~$50M via private placement and ATM; cash runway into late Q3 2026
Private placement with RA Capital Management closed March 26: 1.03M shares at $6.785, pre-funded warrants for 3.39M shares, and warrants for 4.42M shares at $10.00 exercise.
Karyopharm SENTRY trial meets spleen endpoint, misses symptom; DLBCL withdrawal agreed
SENTRY trial: 50% SVR35 at wk24 vs 28% for ruxolitinib alone (p<0.0001); Abs-TSS comparable, not significant.
Karyopharm defers debt payments, requires $25M equity raise to extend runway past mid-2026
Second Amendment to Credit Agreement defers June 2026 principal payment to September 10, 2026; interest due June 30 paid in kind.
FY2025 total revenue $146.1M (up from $145.2M); U.S. XPOVIO net product revenue $114.9M (up from $112.8M).
Preliminary total revenue for 2025 ~$145M; Q4 2025 ~$33M. U.S. XPOVIO net product revenue 2025 ~$115M; Q4 ~$32M.
Karyopharm Q3 net loss $33.1M; XPOVIO revenue up 8.5%; SENTRY data March 2026
Total rev $44.0M ($38.8M Q3 2024); U.S. XPOVIO net product rev $32.0M (+8.5% vs $29.5M).
Karyopharm closes $131M debt financing; issues 9% convertible notes, waives defaults
Borrowed $12.5M under amended credit agreement; issued $15M 2028 and $103.5M 2029 convertible notes at 9%.
KPTI closes $67.5M debt package, note exchanges & $8.75M equity; runway into Q2 2026
$27.5M new term loan (SOFR+10.25%), $25M interest/royalty deferrals, $15M liquidity covenant relief.
Karyopharm Q2 net loss $37.3M; explores financing/strategic alternatives; cash $52M
Total revenue $37.9M; US XPOVIO net product revenue $29.7M (+6% YoY). Net loss $37.3M ($4.32/share).
Karyopharm cuts workforce 20%, explores strategic alternatives including sale
Reducing workforce by ~20% as part of ongoing expense management; one-time costs immaterial.
Total revenue $30.0M; U.S. XPOVIO net product revenue $21.1M, impacted by $5.0M increase in product return reserve for expired 80 mg and 100 mg units.
Karyopharm Q4/FY2024 rev $145M; guides FY2025 rev $140-155M; trial updates
FY2024 total revenue $145.2M (flat YoY); net product revenue $112.8M (vs $112M). Q4 net product rev $29.3M (+17% YoY).
Karyopharm shareholders approve reverse stock split and share increase
Approved increase in authorized capital stock to 805M shares (common to 800M).
Karyopharm estimates FY2024 total rev ~$145M; Phase 3 MF data in 2H 2025
Preliminary FY2024 total revenue ~$145M, XPOVIO net product rev ~$113M; Q4 rev ~$30M, XPOVIO ~$29M.
Karyopharm appoints Lori Macomber as CFO effective Jan 3, 2025
Macomber previously CFO at Legend Biotech, will serve as EVP, CFO and Treasurer.
Karyopharm Q3 total revenue $38.8M, net loss $32.1M; narrows FY2024 guidance
U.S. XPOVIO net product revenue $29.5M in Q3, down from $30.2M in Q3 2023; total revenue up to $38.8M from $36.0M.
Co-primary endpoint changed from TSS50 to Abs-TSS following FDA alignment; SVR35 remains co-primary.
Karyopharm receives Nasdaq deficiency notice for bid price below $1.00
Stock closed below $1.00 for 32 consecutive business days, violating Bid Price Rule 5450(a)(1).
Karyopharm CFO Michael Mason to resign Nov 5; transition agreement signed
Michael Mason, EVP/CFO/Treasurer, notified resignation effective November 5, 2024; will serve until then.
Karyopharm Q2 revenue $42.8M, net income $23.8M on debt gain; raises FY guidance low end
Q2 2024 total revenue $42.8M (Q2 2023: $37.6M); US XPOVIO net product revenue $28.0M (Q2 2023: $28.5M).
Exchanged ~$148M of 3.00% convertible notes due 2025 for $111M of new 6.00% secured convertible notes due 2029.
Karyopharm Q1 total revenue $33.1M, net loss $0.32/share; extends debt maturities to 2028/2029
Q1 2024 total revenue $33.1M (vs $38.7M Q1 2023); U.S. XPOVIO net product revenue $26.0M (vs $28.3M Q1 2023).
Karyopharm closes $100M term loan, exchanges $148M old notes for $111M new 6% notes + warrants
$100M senior secured term loan at SOFR+9.25%, matures May 2028; liquidity covenant $25M minimum.
Karyopharm reports FY2023 total rev $146M, XPOVIO net $112M; guides 2024 total $140-160M
Full year 2023 total revenue $146.0M (down from $157.1M YoY); net loss $143.1M ($1.25/sh) vs $165.3M loss in 2022.
Karyopharm receives Nasdaq deficiency notice for bid price below $1.00 per share
Received deficiency letter on Dec 6, 2023 for failing to meet Nasdaq's $1.00 minimum bid price rule for 30 consecutive business days.
Karyopharm Q3 revenue $36.0M, net loss $0.30/sh; FY guidance reaffirmed
U.S. XPOVIO net product revenue $30.2M, down from $32.0M year-over-year due to PAP use and 340B discounts.
Karyopharm Q2 total rev $37.6M; net loss $32.6M; cuts workforce 20%, guides FY rev $145-160M
Q2 total rev $37.6M (down 5% YoY); net loss $32.6M ($0.29/sh) improved from $49.1M ($0.62/sh).
Karyopharm cuts FY2023 revenue guidance on higher patient assistance; Q1 net loss narrows
Q1 total revenue $38.7M, XPOVIO net product revenue $28.3M flat YoY; net loss $34.1M ($0.30/sh) vs $41.4M loss YoY.
Karyopharm FY2022 total revenue $157.1M, net loss $165.3M; FY2023 guidance $160-175M
U.S. XPOVIO net product revenue $120.4M in FY2022, up 22% YoY from $98.4M.
Karyopharm reports preliminary FY2022 revenue ~$157.7M, extends cash runway to late 2025
Preliminary FY2022 total revenue ~$157.7M; XPOVIO US net revenue ~$120.4M, up 22% YoY.
At week 24, 92% (11/12) evaluable patients achieved ≥35% spleen volume reduction (SVR35).
On November 20, 2024, Karyopharm Therapeutics Inc. (the “Company”) announced the appointment of Kristin Abate, the Company’s Vice President, Accounting, Corporate Controller and Assistant Treasurer, as the Company’s Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024.
On August 26, 2024, Michael Mason notified Karyopharm Therapeutics Inc. (the “Company”) of his intention to resign as the Company’s Executive Vice President, Chief Financial Officer and Treasurer to pursue other professional interests.
On December 5, 2023, Peter K Honig, M.D., MPH, a member of the Board of Directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”), notified the Company of his resignation from the Board, effective as of December 31, 2023.
elected Zhen Su, M.D., M.B.A, as an independent director of the Company to fill the newly created vacancy.
Stuart Poulton, who has served as the Company’s Senior Vice President, Strategy and Portfolio Management since February 2022, has been promoted to Executive Vice President, Chief Development Officer, effective July 27, 2022.
On July 26, 2022, Karyopharm Therapeutics Inc. (the “Company”) and Ran Frenkel agreed that Mr. Frenkel will cease to serve as the Company’s Executive Vice President, Chief Development Officer effective August 15, 2022.
provides for Dr. Kauffman’s separation from employment as Senior Clinical Advisor on May 31, 2022
provides for Dr. Shacham’s separation from employment as Chief Scientific Officer on the Separation Date
On March 22, 2022, Michael G. Kauffman, M.D., Ph.D. notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors, effective immediately.
On December 2, 2021, Mikael Dolsten, MD, PhD, notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors (the “Board”), effective immediately.
On December 3, 2021, the Board, upon the recommendation of the Nominating, Corporate Governance & Compliance Committee of the Board, elected Peter K Honig, M.D., MPH, as an independent director of the Company to fill a vacancy on the Board.
Max materiality 0.95 · Median 0.65 · Most common event earnings